R
Robert J. Fontana
Researcher at University of Michigan
Publications - 396
Citations - 35569
Robert J. Fontana is an academic researcher from University of Michigan. The author has contributed to research in topics: Liver transplantation & Hepatitis C. The author has an hindex of 82, co-authored 355 publications receiving 31311 citations. Previous affiliations of Robert J. Fontana include Harvard University & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
Chun-Tao Wai,Joel K. Greenson,Robert J. Fontana,John D. Kalbfleisch,Jorge A. Marrero,Hari S. Conjeevaram,Anna S.F. Lok +6 more
TL;DR: It is shown that a simple index using readily available laboratory results can identify CHC patients with significant fibrosis and cirrhosis with a high degree of accuracy and may decrease the need for staging liver biopsy specimens among patients with CHC.
Journal ArticleDOI
Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States
George Ostapowicz,Robert J. Fontana,Frank V. Schioødt,Anne M. Larson,Timothy J. Davern,Steven Han,Timothy M. McCashland,A. Obaid Shakil,J. Eileen Hay,Linda S. Hynan,Jeffrey S. Crippin,Andres T. Blei,Grace Samuel,Joan S. Reisch,William M. Lee,Raj Santyanarayana,Cary Caldwell,Lawton Shick,Nathan M. Bass,Smita Rouillard,E Atillasoy,Steven L. Flamm,Kent G. Benner,Hugo R. Rosen,Paul Martin,Rise Stribling,Eugene R. Schiff,Maria Torres,Victor J. Navarro,Brendan M. McGuire,Raymond T. Chung,Diane R. Abraczinskas,Jules L. Dienstag +32 more
TL;DR: The primary aim was to compare presenting clinical features and liver transplantation in patients with acute liver failure related to acetaminophen hepatotoxicity, other drugs, indeterminate factors, and other causes.
Journal ArticleDOI
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.
Anne M. Larson,Julie Polson,Robert J. Fontana,Timothy J. Davern,Ezmina Lalani,Linda S. Hynan,Joan S. Reisch,Frank V. Schiødt,George Ostapowicz,A. Obaid Shakil,William M. Lee +10 more
TL;DR: In conclusion, acetaminophen hepatotoxicity far exceeds other causes of acute liver failure in the United States, and education of patients, physicians, and pharmacies to limit high‐risk use settings is recommended.
Journal ArticleDOI
Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States
Naga Chalasani,Robert J. Fontana,Herbert L. Bonkovsky,Herbert L. Bonkovsky,Herbert L. Bonkovsky,Paul B. Watkins,Timothy J. Davern,Jose Serrano,Hongqiu Yang,James Rochon +9 more
TL;DR: This report summarizes the causes, clinical features, and outcomes from the first 300 patients enrolled in a prospective study to recruit patients with suspected idiosyncratic drug-induced liver injury and create a repository of biological samples for analysis.
Journal ArticleDOI
Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
Michael P. Curry,Jacqueline G. O'Leary,Natalie Bzowej,Andrew J. Muir,Kevin M. Korenblat,Jonathan M. Fenkel,K. R. Reddy,E. Lawitz,Steven L. Flamm,T. Schiano,L. Teperman,Robert J. Fontana,E. Schiff,Michael W. Fried,Brian P. Doehle,D. An,J. McNally,A. O. Osinusi,Diana M. Brainard,John G. McHutchison,Robert S. Brown,Michael Charlton +21 more
TL;DR: Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with so-called "superdrugs" for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis.